Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Toshiaki Saito |
| Publication date | February 16, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |